Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Syon Capital LLC

Syon Capital LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,276 shares of the pharmaceutical company’s stock after purchasing an additional 111 shares during the quarter. Syon Capital LLC’s holdings in Vertex Pharmaceuticals were worth $926,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in VRTX. OFI Invest Asset Management purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $25,000. Arlington Trust Co LLC boosted its position in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 33 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Baystate Wealth Management LLC grew its stake in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 25 shares during the period. Finally, NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $34,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.8 %

NASDAQ:VRTX traded down $3.06 during trading hours on Thursday, hitting $397.70. The stock had a trading volume of 787,274 shares, compared to its average volume of 1,234,807. The company has a market cap of $102.79 billion, a PE ratio of 28.85, a price-to-earnings-growth ratio of 1.91 and a beta of 0.35. The business has a 50 day simple moving average of $412.66 and a two-hundred day simple moving average of $398.38. Vertex Pharmaceuticals Incorporated has a 1-year low of $316.43 and a 1-year high of $448.40. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period last year, the business earned $3.33 EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. Barclays lifted their price target on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. UBS Group cut their price objective on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 20th. Finally, Canaccord Genuity Group reaffirmed a “sell” rating and set a $371.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.